K Stenberg, Sven Skog, Bernhard Tribukait,
The mechanism of toxicity of foscarnet was studied by monitoring its effects on the cell cycle of exponentially growing, semisynchronous human embryo cells in culture. The effects of foscarnet on the cell cycle were dependent on the ... phase cells provided additional evidence that 1 mM foscarnet did not specifically inhibit DNA synthesis. Cell division was greatly reduced at 2.5 mM foscarnet, and the G2 phase was markedly affected, whereas ... other hand, at a concentration of 5 mM foscarnet, the cell flow was greatly reduced in the ...
Tópico(s): Cell death mechanisms and regulation
1985 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
... daily maintenance treatment was required to sustain remission. Foscarnet (4) is a virostatic agent of importance in ... bone marrow transplantation (5). We have recently used foscarnet to treat a patient with the acquired immunodeficiency ... Intern Med. 1985;103:381-2. LinkGoogle Scholar4. Foscarnet [Editorial]. Lancet. 1985;2:648-9. MedlineGoogle Scholar5. ... B, GAHRTON G, WAHREN B, and LERNESTEDT J. Foscarnet for cytomegalovirus infections. Lancet. 1985;1:1503-4. ... CMV) antibody (MSL 109): Enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replicationSystemic viral ...
Tópico(s): Neutrophil, Myeloperoxidase and Oxidative Mechanisms
1985 - American College of Physicians | Annals of Internal Medicine
JohnC. Beldekas, ElinorM. Levy, Paul H. Black, GeoVon Krogh, Eric Sandström,
The drug foscarnet (trisodium phosphonoformate) has been shown to be effective against human T-lymphotropic virus type III (HTLV-III) in ... H-9 cultures. The in vivo effect of foscarnet on T-lymphocyte numbers in acquired immunodeficiency syndrome ( ... general expansion of immature precursor T cells. When foscarnet is added to peripheral blood lymphocytes in soft ... whom T-cell colony forming ability is diminished foscarnet produces a significant increase in T-cell colony ... 12 AIDS patients showed a positive response to foscarnet despite the fact that their capacity to produce ...
Tópico(s): HIV Research and Treatment
1985 - Elsevier BV | The Lancet
Brief Reports15 June 1990Nephrogenic Diabetes Insipidus Associated with Foscarnet Treatment of Cytomegalovirus RetinitisRobert V. Farese Jr., MD, ... complication of treatment of cytomegalovirus (CMV) retinitis with foscarnet (trisodium phosphonoformate).Case ReportA 37-year-old homosexual ... 10:82-95. CrossrefMedlineGoogle Scholar2. JacobsonO'DonnellMills MJJ. Foscarnet treatment of cytomegalovirus retinitis in patients with the ... Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis. 1988;157:569-72. CrossrefMedlineGoogle ...
Tópico(s): Glycogen Storage Diseases and Myoclonus
1990 - American College of Physicians | Annals of Internal Medicine
Gilbert Deray, Franck Martinez, Christine Katlama, Béatrice Levaltier, H Beaufils, Martin Danis, Michel Rozenheim, A Baumelou, Elisabeth Dohin, M Gentilini, Claude Jacobs,
Foscarnet is a pyrophosphate analogue that has been successfully used in severe cytomegalovirus (CMV) infections. Little is known of the incidence and mechanisms of foscarnet-induced nephrotoxicity as most data comes from recipients ... evolution of renal function after 56 courses of foscarnet. In addition, we have prospectively studied the protective effects of hydration on foscarnet nephrotoxicity (2.5 liters of saline/day during the night before the foscarnet therapy and throughout the course of treatment). Foscarnet- ...
Tópico(s): Biomedical Research and Pathophysiology
1989 - Karger Publishers | American Journal of Nephrology
Heng-Xiang Wang, Ling Zhu, Mei Xue, Jing Liu, Zi‐Kuan Guo,
... Scopus (50) Google Scholar] or in combination with foscarnet [7Bacigalupo A. Bregante S. Tedone E. et al.Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after hemopoietic stem ... If CMV pp65–positive cells were detected, then foscarnet treatment was started at a dose of 60 ... saline solution/m2 of body surface area. During foscarnet treatment, peripheral blood cell count, creatinine levels, and ... median, 12 days) after initiation of low-dose foscarnet therapy. In a 6- to 24-month follow- ...
Tópico(s): Virus-based gene therapy research
2009 - Elsevier BV | Biology of Blood and Marrow Transplantation
Egor P. Tchesnokov, Aleksandr Obikhod, Raymond F. Schinazi, Matthias Götte,
... 400-fold less sensitive to the pyrophosphate analog foscarnet, when compared with UL54. The RB69 enzyme is ... and helix P of UL54 are resensitized against foscarnet and acyclovir. Changing a region of three amino ... 400-fold less sensitive to the pyrophosphate analog foscarnet, when compared with UL54. The RB69 enzyme is ... and helix P of UL54 are resensitized against foscarnet and acyclovir. Changing a region of three amino ... PubMed Scopus (43) Google Scholar). The pyrophosphate analog foscarnet (phosphonoformic acid, PFA) is the third approved anti- ...
Tópico(s): Biochemical and Molecular Research
2009 - Elsevier BV | Journal of Biological Chemistry
Mark Z. Jacobson, John G. Gambertoglio, Francesca Aweeka, Dennis Causey, Anthony A. Portale,
Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes ... mechanism of these abnormalities in humans treated with foscarnet for opportunistic herpes virus infections, we analyzed anaerobic ... and after single and multiple doses of iv foscarnet and performed a series of in vitro experiments ... who received a 90 mg/kg dose of foscarnet and by a mean 0.28 mmol/L ... showed a highly significant inverse linear relationship between foscarnet and ionized calcium concentrations, but no correlation between ...
Tópico(s): Bone health and treatments
1991 - Oxford University Press | The Journal of Clinical Endocrinology & Metabolism
The primary dose-limiting adverse effects associated with foscarnet treatment of cytomegalovirus retinitis in patients with AIDS ... observed in 10-20% of AIDS patients receiving foscarnet via intermittent i.v. infusion. Nephrotoxicity can be ... by ensuring that adequate hydration is provided throughout foscarnet therapy. Transient decreases in serum or plasma ionized ... levels appear to occur in all patients during foscarnet infusion, with these decreases being observed in the ... levels of total calcium and other minerals during foscarnet treatment, and the occurrence of symptomatic hypocalcemia should ...
Tópico(s): Herpesvirus Infections and Treatments
1992 - Lippincott Williams & Wilkins | JAIDS Journal of Acquired Immune Deficiency Syndromes
... famciclovir, ganciclovir with the prodrug valganciclovir, cidofovir and foscarnet. All the available drugs, except foscarnet, are nucleoside analogues and require phosphorylation by viral ... recommended drug for acyclovir-resistant HSV has been foscarnet (Safrin et al, 1990; Verdonck et al, 1993; ... patients with mutants resistant to both acyclovir and foscarnet (Chakrabarti et al, 2000; Chen et al, 2000). ... by the more toxic agents (ganciclovir and/or foscarnet). It was reported in acquired immunodeficiency syndrome (AIDS) ...
Tópico(s): Polyomavirus and related diseases
2002 - Wiley | British Journal of Haematology
The present study compared foscarnet with ganciclovir for preemptive therapy of cytomegalovirus (CMV) infection after allogeneic blood or marrow stem cell transplantation (SCT). Patients with ... to intravenous therapy for 2 weeks with either foscarnet at 60 mg/kg or ganciclovir at 5 ... patients received an additional 2 weeks of intravenous foscarnet at 90 mg/kg or ganciclovir at 6 ... total of 213 patients were treated with either foscarnet (n = 110) or ganciclovir (n = 103). Kaplan-Meier ... patients on ganciclovir versus 4 (4%) patients on foscarnet (P = .04), and impaired renal function was observed ...
Tópico(s): Hematopoietic Stem Cell Transplantation
2002 - Elsevier BV | Blood
Kenneth Purdy, John R. Heckenlively, Joseph A. Church, Margaret Keller,
... necrosis was suspected. Ganciclovir was discontinued, and intravenous foscarnet was added to the intravenous acyclovir. She was ... therapy (HAART) was administered, and intravenous acyclovir and foscarnet were continued for 6 weeks. Daily maintenance foscarnet was continued for 1 year. Intravenous antiviral medications ... light from the left eye. High dose intravenous foscarnet was added, and HAART was reinitiated. An intravitreal ... was discontinued, and acyclovir was added to the foscarnet. Despite several months of therapy with foscarnet and ...
Tópico(s): Retinal and Optic Conditions
2003 - Lippincott Williams & Wilkins | The Pediatric Infectious Disease Journal
Mark Z. Jacobson, Michael Wulfsohn, Judith Feinberg, Roger B. Davis, Maureen Power, Susan Owens, Dennis Causey, Margo Heath‐Chiozzi, Robert L. Murphy, Tony Cheung, Douglas T. Dieterich, Stephen A. Spector, George McKinley, David M. Parenti, Clyde S. Crumpacker,
Objective: To document response to foscarnet salvage therapy in patients with cytomegalovirus (CMV) retinitis who are intolerant of or resistant to ganciclovir. Methods: Patients with AIDS and ... to ganciclovir therapy received an induction course of foscarnet, 60mg/kg every 8h for 14 days, and subsequent chronic maintenance foscarnet therapy at a daily dose of 60, 90 ... 87 patients were randomly assigned to receive maintenance foscarnet at a dose of 60 or 90mg/kg/ ... differ significantly among groups assigned to different maintenance foscarnet doses. Among patients with retinitis progression documented ophthalmologically ...
Tópico(s): Neonatal Health and Biochemistry
1994 - Lippincott Williams & Wilkins | AIDS
P Fan-Harvard, Vaishali Sanchorawala, J. Oh, E M Moser, Susan Smith,
OBJECTIVE: To report a possible interaction between foscarnet and ciprofloxacin in two patients with AIDS, cytomegalovirus (CMV) retinitis, and disseminated Mycobacterium avium complex (MAC) infection and to review the available literature related to foscarnet associated seizures. DATA SOURCE: Case report information was ... literature published between 1980 and 1993. DATA SYNTHESIS: Foscarnet is a synthetic antiviral agent with activity against ... viruses and HIV. The incidence of seizures with foscarnet infusion is high, ranging from 13 to 15 ...
Tópico(s): Antibiotics Pharmacokinetics and Efficacy
1994 - SAGE Publishing | Annals of Pharmacotherapy
Hiroto Narimatsu, Masahiro Kami, Daisuke Kato, Tomoko Matsumura, Naoko Murashige, Eiji Kusumi, Koichiro Yuji, Akiko Hori, Taro Shibata, Kazuhiro Masuoka, Atsushi Wake, Shigesaburo Miyakoshi, S Morinaga, Shuichi Taniguchi,
Abstract: Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients ... transplantation (RI‐CBT). Patients preemptively received reduced‐dose foscarnet 30 mg/kg twice daily when CMV antigenemia ... a median of day 34, and 29 received foscarnet preemptively. The median level of CMV antigenemia at the initiation of foscarnet was 30. Median duration of foscarnet administration was 24 days. Adverse effects included electrolyte ...
Tópico(s): Neonatal Health and Biochemistry
2007 - Wiley | Transplant Infectious Disease
Valérie Martinez, Jean‐Michel Molina, Catherine Scieux, Patricia Ribaud, Florence Morfin,
... 242-249Crossref PubMed Scopus (177) Google Scholar Although foscarnet (FCV) or cidofovir (CDV) are usually effective to ... Schrager L. Crumpacker C.S. Successful treatment with foscarnet of an acyclovir resistant mucocutaneous infection with herpes ... P. et al.Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in ... P. et al.Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in ... 6Safrin S. Kemmerly S. Plotkin B. et al.Foscarnet-resistant herpes simplex virus infection in a patient ...
Tópico(s): Nail Diseases and Treatments
2006 - Elsevier BV | The American Journal of Medicine
François Raffi, A M Taburet, Bijan Ghaleh, Alain Huart, E Singlas,
The diffusion of foscarnet into cerebrospinal fluid (CSF) was studied in 27 patients with AIDS. Foscarnet was administered intravenously at various dosages at 12- ... in plasma and CSF at the end of foscarnet infusion or 1, 3, 5, 6, and 12 ... seven samples were obtained. The median concentration of foscarnet in CSF was 80 mumol/liter (range, 0 to 500 mumol/liter). The CSF foscarnet concentration was greater than the 50% inhibitory concentration ... for cytomegalovirus in most cases. The penetration of foscarnet into CSF, as expressed by the ratio of ...
Tópico(s): HIV Research and Treatment
1993 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
Ulrich R. Hengge, N. H. Brockmeyer, R. Maleßa, Ursula Ravens, M. Goos,
Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the ... the blood-brain barrier, we determined concentrations of foscarnet in cerebrospinal fluid and in plasma specimens from ... after a single infusion of 90 mg of foscarnet per kg of body weight and at steady ... blood-brain barrier. After a single infusion of foscarnet, levels in plasma ranged from 297 to 1, ... 0.23 +/- 0.16). At steady state, mean foscarnet levels in plasma were 464 +/- 219 micrograms/ml ( ... administration and at steady state, the concentrations of foscarnet attained in cerebrospinal fluid are sufficient for complete ...
Tópico(s): Autoimmune Neurological Disorders and Treatments
1993 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
Michael A. Polis, Mark D. DeSmet, Barbara Baird, Susan D. Mellow, Judith Falloon, Richard T. Davey, Joseph A. Kovacs, Alan G. Palestine, Robert B. Nussenblatt, Henry Masur, H. Clifford Lane,
... syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health. Foscarnet was continued for as long as it was ... Seventeen patients received zidovudine during or after receiving foscarnet, 2 patients received dideoxyinosme, 2 patients ridovudine and ... patients received no specific antiretroviral agent. Patients received foscarnet for a mean of 6.2 months (median, ... to ganciclovir therapy at some time after receiving foscarnet. The median time from the diagnosis of CMV ...
Tópico(s): Pneumocystis jirovecii pneumonia detection and treatment
1993 - Elsevier BV | The American Journal of Medicine
Masayuki Saijo, Tatsuo Suzutani, Shigeru Morikawa, Ichiro Kurane,
Foscarnet is widely used for the treatment of acyclovir-resistant herpesvirus infections, and foscarnet-resistant herpesvirus infections are a serious concern in ... simplex virus type 1 (HSV-1) resistant to foscarnet were selected from foscarnet- and acyclovir-sensitive HSV-1 strain TAS by exposure to foscarnet, and the DNA polymerase genes were analyzed. The sensitivities of these mutants to foscarnet, cidofovir, S2242, acyclovir, ganciclovir, and penciclovir were determined. ... in the DNA polymerase responsible for resistance to foscarnet was located between the pre-IV region and ...
Tópico(s): Polyomavirus and related diseases
2005 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
Adam C. Alexander, Aletha Y. Akers, Gary R. Matzke, Francesca Aweeka, Donald S. Fraley,
AbstractOBJECTIVE:To report the disposition of foscarnet in a patient undergoing peritoneal dialysis.CASE SUMMARY:A 34-year-old man with AIDS received foscarnet for the treatment of esophageal cytomegalovirus. We characterized the clearance of foscarnet in this patient during continuous cyclic peritoneal dialysis ( ... and continuous ambulatory peritoneal dialysis (CAPD).DISCUSSION:The foscarnet half-lives during CCPD and CAPD were 41. ... interdialytic period. The CCPD and CAPD clearances of foscarnet were 5.8 and 4.5 mL/min, ...
Tópico(s): Blood disorders and treatments
1996 - SAGE Publishing | Annals of Pharmacotherapy
Howard Desatnik, Robert E. Foster, Careen Y. Lowder,
... To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis ... was treated with intravitreal injections of ganciclovir and foscarnet, which were then combined when the retinitis became ... reactivation of retinitis in the left eye, intravitreal foscarnet was effective until recurrent retinitis threatened the center ... progress until combined intravitreal injections of ganciclovir and foscarnet were administered. Conclusion Combined intravitreal injections of ganciclovir ...
Tópico(s): Neonatal Health and Biochemistry
1996 - Elsevier BV | American Journal of Ophthalmology
Andrea Bacigalupo, Stefania Bregante, Elisabetta Tedone, Ana María Ángel‐Isaza, M. T. Van Lint, G Trespi, D Occhini, Francesca Gualandi, Teresa Lamparelli, Alberto M. Marmont,
... mortality (TRM) rate, despite treatment with ganciclovir or foscarnet. In an attempt to reduce TRM, 32 allogeneic ... of 49 days, were given combination treatment with foscarnet and ganciclovir for 15 days. The prescribed dose was 180 mg/kg/day of foscarnet and 10 mg/kg/day of ganciclovir: the ... levels and peripheral blood counts, was 64% for foscarnet and 53% for ganciclovir. Maintenance was given with foscarnet and ganciclovir on alternate days for an additional ... 14 patients off maintenance therapy: the dose of foscarnet (but not ganciclovir) received in the first 15 ...
Tópico(s): Polyomavirus and related diseases
1996 - Wolters Kluwer | Transplantation
Henry H. Balfour, Courtney V. Fletcher, Alejo Erice, W. Keith Henry, Edward P. Acosta, Scott A. Smith, M A Holm, Guy Boivin, David H. Shepp, Clyde S. Crumpacker, Cheryl A. Eaton, Sarah Martin-Munley,
Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia. CMV ... antiretroviral therapy were enrolled. Twenty-two subjects received foscarnet, which was well tolerated and decreased the CMV ... significant pharmacodynamic relationship was found between the peak foscarnet concentration and a decrease in the level of CMV antigenemia (P < 0.05). Foscarnet had no effect on quantitative HIV-1 microcultures ... plasma HIV-1 RNA concentrations and both peak foscarnet concentration (P < 0.01) and the area under ...
Tópico(s): HIV/AIDS drug development and treatment
1996 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
Sofie Mathiesen, Birgit Thorup Røge, Nina Weis, Jens Lundgren, Niels Obel, Jan Gerstoft,
We used foscarnet as induction therapy or as maintenance therapy in different dosing regimens in seven severely immunocompromised multidrug-resistant HIV- ... cells/mm3were observed during maintenance therapy, suggesting that foscarnet could be an option in salvage therapy in patients with no treatment options left. Foscarnet is a pyrophosphate analogue and inhibits several viral ... binding close to the binding site of pyrophosphate. Foscarnet has been used in the treatment of cytomegalovirus ... RNA levels [1–3]. However, the use of foscarnet has been limited because of the need for ...
Tópico(s): Cytomegalovirus and herpesvirus research
2004 - Lippincott Williams & Wilkins | AIDS
Subhas Banerjee, J. Thomas LaMont,
... phosphorylation of the drug to its active form. Foscarnet inhibits viral DNA polymerase and does not require ... for resistant strains. In a randomized trial comparing foscarnet with vidarabine in 14 AIDS patients with acyclovir-resistant HSV infections, foscarnet, but not vidarabine, was found effective in all ... Landry B Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex ... Scholar For the treatment of acyclovir-resistant strains, foscarnet is given in a dose of 40–60 ...
Tópico(s): Microscopic Colitis
2000 - Elsevier BV | Gastroenterology
Mark M. Huycke, Tarek Naguib, Mathias M. Stroemmel, Kenneth E. Blick, Katherine Monti, Sarah Martin-Munley, Chris Kaufman,
Foscarnet (trisodium phosphonoformate hexahydrate) is an antiviral agent used to treat cytomegalovirus disease in immunocompromised patients. One ... acute ionized hypocalcemia and hypomagnesemia following intravenous administration. Foscarnet-induced ionized hypomagnesemia might contribute to ionized hypocalcemia ... target organ resistance. Prevention of ionized hypomagnesemia following foscarnet administration could blunt the development of ionized hypocalcemia. ... decline in ionized calcium and/or magnesium following foscarnet infusions, MgSO(4) at doses of 1, 2, ...
Tópico(s): Parathyroid Disorders and Treatments
2000 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
Kirstin L. Tawse, Caroline R. Baumal,
... Treatment of macular threatening CMV infection with intravitreal foscarnet injections and intravenous ganciclovir for 6 weeks led ... of life, requiring a second course of intravitreal foscarnet injections and intravenous ganciclovir. Both the initial presentation ... Treatment of macular threatening CMV infection with intravitreal foscarnet injections and intravenous ganciclovir for 6 weeks led ... of life, requiring a second course of intravitreal foscarnet injections and intravenous ganciclovir. Both the initial presentation ...
Tópico(s): Neonatal Health and Biochemistry
2014 - Elsevier BV | Journal of American Association for Pediatric Ophthalmology and Strabismus
Vincent C. Emery, Mark Zuckerman, Graham Jackson, Celia Aitken, Husam Osman, Antonio Pagliuca, Mike Potter, Karl S. Peggs, Andrew Clark,
... aciclovir prophylaxis or a combination of ganciclovir and foscarnet have been employed in high-risk paediatric and ... as for intravenous ganciclovir (Mattes et al, 2005). Foscarnet does not require phosphorylation and is virustatic through ... Two randomized studies have compared the outcomes of foscarnet versus ganciclovir pre-emptive therapy of CMV infection ... Moretti et al, 1998; Reusser et al, 2002). Foscarnet 90 mg/kg was compared with ganciclovir 5 ... A larger EBMT study compared 60 mg/kg foscarnet (n = 110) with ganciclovir 5 mg/kg (n = ...
Tópico(s): Toxoplasma gondii Research Studies
2013 - Wiley | British Journal of Haematology
Laurence Gérard, Dominique Salmon‐Céron,
Foscarnet, licenced by Astra pharmaceutical products, is a pyrophosphate analogue that selectively inhibits replication of viruses in ... cellular phosphorylation for antiviral activity. Oral bioavailability of foscarnet is low (12–22%), and foscarnet must be administered intravenously. It is mainly eliminated ... mg/kg b.i.d. In AIDS patients, foscarnet is an effective treatment of HCMV retinitis. Healing ... rates of 57–95% have been reported with foscarnet. The optimal maintenance dosage of foscarnet necessary in ...
Tópico(s): Neonatal Health and Biochemistry
1995 - Elsevier BV | International Journal of Antimicrobial Agents